The double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial showed a reduction in cardiovascular death, myocardial infarction and stroke in patients with ACS, compared to standard therapy plus placebo.
For major bleeding events not associated with Coronary Artery Bypass Graft surgery, there was an increase in such events in patients receiving Rivaroxaban against placebo.
The company plans to present the data by the end of this year.